Literature DB >> 20456548

On the development of the European S3 guidelines on the systemic treatment of psoriasis vulgaris: structure and challenges.

D Pathirana1, A Nast, A D Ormerod, N Reytan, P Saiag, C H Smith, P Spuls, B Rzany.   

Abstract

BACKGROUND: The development of evidence based guidelines is a demanding and time consuming process. Therefore it is important to share the knowledge and discuss the structure of these guidelines in detail.
OBJECTIVES: To present a method report on the development process of the European evidence based guidelines on the systemic treatment of psoriasis vulgaris with the aim to offer guidance to other guidelines groups with lesser experience and to critically appraise the methodology of the guidelines development process.
METHODS: The guidelines are based on the previously evaluated literature from three European national evidence based guidelines and an additional systematic search and evaluation of new literature. Further steps included a structured consensus conference and a DELPHI procedure to develop the recommendations, as well as several internal and external reviews. All steps were coordinated by the Division of evidence based medicine in cooperation with a group of methodologists.
RESULTS: A total of 114 studies were included, serving as base for the efficacy chapters of the intervention. The recommendations, based on the efficacy and the level of evidence of the included studies were discussed and finally consented by the guidelines group. After subsequent reviews the guidelines were presented to the European Dermatology Forum, European Academy of Dermatology and Venereology and Union Européenne des Médicins Spécialistes for approval and published in October 2009.
CONCLUSION: The development of European evidence based guidelines requires a coordinated structure which can be achieved by the integration of an experienced group of methodologists. Nevertheless further improvements are imaginable and might be considered for an update or other European evidence based guidelines.
© 2010 The Authors. Journal compilation © 2010 European Academy of Dermatology and Venereology.

Entities:  

Mesh:

Year:  2010        PMID: 20456548     DOI: 10.1111/j.1468-3083.2010.03671.x

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN: 0926-9959            Impact factor:   6.166


  7 in total

1.  Dynamic QuantiFERON Response in Psoriasis Patients Taking Long-Term Biologic Therapy.

Authors:  Lorenzo Drago; Lucia Nicola; Valentina Signori; Elisa Palazzi; Cecilia Garutti; Samantha Spadino; Gianfranco Altomare
Journal:  Dermatol Ther (Heidelb)       Date:  2013-02-23

2.  Comparison of Treatment Goals for Moderate-to-Severe Psoriasis between Korean Dermatologists and the European Consensus Report.

Authors:  Sang Woong Youn; Bo Ri Kim; Joo Heung Lee; Hae Jun Song; Yong Beom Choe; Ji Ho Choi; Nack In Kim; Kwang Joong Kim; Jai Il Youn
Journal:  Ann Dermatol       Date:  2015-03-24       Impact factor: 1.444

3.  [Methotrexate and psoriasis: about 46 cases].

Authors:  Kawtar Inani; Mariame Meziane; Fatimazahra Mernissi
Journal:  Pan Afr Med J       Date:  2014-09-25

4.  Annual biologic treatment cost for new and existing patients with moderate to severe plaque psoriasis in Greece.

Authors:  Vassilis Fragoulakis; Efklidis Raptis; Elli Vitsou; Nikolaos Maniadakis
Journal:  Clinicoecon Outcomes Res       Date:  2015-01-08

5.  Dermatology Life Quality Index and disease coping strategies in psoriasis patients.

Authors:  Sopiko Liluashvili; Tina Kituashvili
Journal:  Postepy Dermatol Alergol       Date:  2019-08-30       Impact factor: 1.837

6.  Adalimumab ameliorates abdominal aorta cross clamping which induced liver injury in rats.

Authors:  Erkan Cure; Medine Cumhur Cure; Levent Tumkaya; Yildiray Kalkan; Ibrahim Aydin; Aynur Kirbas; Arif Yilmaz; Suleyman Yuce; Ahmet Fikret Yücel
Journal:  Biomed Res Int       Date:  2014-01-16       Impact factor: 3.411

7.  The association of socioeconomic and clinical characteristics with health-related quality of life in patients with psoriasis: a cross-sectional study.

Authors:  Sungwon Jung; Seung-Mi Lee; David Suh; Hyun Taek Shin; Dong-Churl Suh
Journal:  Health Qual Life Outcomes       Date:  2018-09-12       Impact factor: 3.186

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.